UCB's Global Corporate Website
Welcome to UCB in the United States
Jun 27
Kimberly Moran, Head of U.S. Rare Diseases
Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis

Patient insights, science, and innovation have led us to this moment: an FDA-approved treatment for an adult patient population who continues to experience high unmet needs in generalized myasthenia gravis.

Our purpose here at UCB is to create value for patients, and that’s why we’re so proud that we have delivered on our mission to garner FDA approval of our first treatment for adult patients with generalized myasthenia gravis. This new and approved medicine will be made available very shortly, and in the next few weeks, our patient support program will also go fully operational to provide personalized support to eligible patients during their treatment journey. 

Keeping the patient at the heart of everything we do, we know that each and every person living with myasthenia gravis has unique perspectives, and we will continue to incorporate their individual experiences, and the moments that matter to them, in the discovery, development, and delivery of our solutions.

We will also continue to listen to the myasthenia gravis community, to not only learn more about them, but also from them—to understand more about their lived experiences. 

I invite you to watch a video of my time with Alexis, who shared his 25-year journey living with this rare condition.


©2023 UCB, Inc., Smyrna, GA 30080. All rights reserved. US-P-RZ-MG-2300147

For a U.S. audience only.

Share:linkedin| twitter| email